Price Target Update on EXACT Sciences Corporation (NASDAQ:EXAS)

EXACT Sciences Corporation (NASDAQ:EXAS) : The highest level EXACT Sciences Corporation (NASDAQ:EXAS) is projected to reach is $18 for the short term and the lowest estimate is at $7. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $11.83 and the possibility the share price can swing is $3.81.

Other Equity analysts have also commented on the company shares. Craig-Hallum upgrades its view on EXACT Sciences Corporation (NASDAQ:EXAS) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. Craig-Hallum raises the current price target of $18 per share on EXACT Sciences Corporation. The rating by the firm was issued on June 16, 2016.

EXACT Sciences Corporation (NASDAQ:EXAS): stock turned positive on Thursday. Though the stock opened at $10.5, the bulls momentum made the stock top out at $11.23 level for the day. The stock recorded a low of $10.27 and closed the trading day at $11.09, in the green by 7.15%. The total traded volume for the day was 6,066,254. The stock had closed at $10.35 in the previous days trading.

The company shares have dropped -64.86% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $32.85 and the one year low was seen on Mar 1, 2016. The 50-Day Moving Average price is $7.05 and the 200 Day Moving Average price is recorded at $7.04. On the companys insider trading activities,The officer (SVP and General Counsel) of Exact Sciences Corp, Coward D Scott sold 1,685 shares at $6.62 on April 1, 2016. The Insider selling transaction had a total value worth of $11,155. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.